Skip to main navigation Skip to search Skip to main content

Dapagliflozin suppressed gastric cancer growth via regulating OTUD5 mediated YAP1 deubiquitination

  • Kaijie Ren
  • , Xueni Wang
  • , Rulan Ma
  • , Huan Chen
  • , Tianhao Min
  • , Yuyi Ma
  • , Xin Xie
  • , Wei Wang
  • , Xiaoyuan Deng
  • , Zhangjian Zhou
  • , Kang Li
  • , Kun Zhu
  • , Nan Hao
  • , Chengxue Dang
  • , Tuanhe Sun
  • , Hao Zhang
  • The First Affiliated Hospital of Xi’an Jiaotong University
  • The Second Affiliated Hospital of Xi'an Jiaotong University
  • Engineering Research Center of Biotherapy and Translational Medicine of Shaanxi Province

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Gastric cancer (GC) is a common malignant disease that has a fifth highest incidence and fourth highest mortality worldwide. The Warburg effect is a common phenomenon observed in tumors, which suggests that tumor cells would enhance glucose uptake by overexpressing multiple glucose transporters. Sodium glucose transporter 2 (SGLT2) is one of glucose transporters which highly expressed in several cancers, but its role in gastric cancer is still unclear. Our research found that there was a high expression level of SGLT2 in gastric cancer tissues. We found that Dapagliflozin (a SGLT2 inhibitor) could suppress gastric cancer cell proliferation and migration in vitro and tumor growth in vivo. In present study, we revealed how dapagliflozin would suppress gastric cancer progression in a novel mechanism. We proved that dapagliflozin decreased the expression level of OTU deubiquitinase 5 (OTUD5), which further increased the ubiquitination and degradation of YAP1. Overexpression of OTUD5 in gastric cancer cells partly reversed the anti-tumor effect of dapagliflozin. Our findings revealed a novel mechanism by which dapagliflozin has an antitumor effect on gastric cancer and proposed a beneficial strategy for the application of dapagliflozin in gastric cancer patients.

Original languageEnglish
Article number177002
JournalEuropean Journal of Pharmacology
Volume983
DOIs
StatePublished - 15 Nov 2024
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Dapagliflozin
  • Gastric cancer
  • OTUD5
  • YAP1

Fingerprint

Dive into the research topics of 'Dapagliflozin suppressed gastric cancer growth via regulating OTUD5 mediated YAP1 deubiquitination'. Together they form a unique fingerprint.

Cite this